The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

T-cell Immunotherapy: Clinical Trial Tracker

  • Lowest Price Guaranteed From USD 949

  • Published
    July 2016

  • Pages
    0

  • View Count
    1601

Example Insights

Available on request

Overview

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. These promising therapeutic strategies, developed under the banner of T-cell immunotherapies, are set to hit the market in the near future.T-cells, also named as the soldiers of the immune system, are featured with specificity and functionally combat infections, cancerous cells and other foreign entities. High therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy.

With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time, expertise and effort, have played a critical role in maturing the design and development of novel CAR-Ts, TCRs and TILs. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania/The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics/Seattle Children’s Hospital), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), CD19-CAR (Takara Bio/Jichi Medical University) and LN-144 (Lion Biotechnologies/National Cancer Institute).

 

Scope of the Report

The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of T-cell Immunotherapy. We have identified a number of T-cell Immunotherapy products and clinical trials that are either being conducted or planned to be conducted for each of these products. For each specific product, we have provided the following information:

  1. Primary Drug
  2. Highest Phase of Development
  3. Developer/Licensee
  4. Target Antigen

For each specific trial, we have provided the following information:

  1. Indication
  2. Type of Indication
  3. Sponsor/Collaborator
  4. Type of Sponsor
  5. Trial Title
  6. Trial Objective
  7. Trial Phase
  8. Trial Status
  9. Start Date
  10. End Date
  11. Enrolment
  12. Age Range
  13. Inclusion Criteria
  14. Exclusion Criteria
  15. StudyDesign
  16. PrimaryEndpoint
  17. SecondaryEndpoint
  18. Treatment Arm(s)
  19. Location(s)
  20. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

  • Sales forecasts of the T-cell Immunotherapy market over the course of next fifteen years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

Contents

Introduction and Pipeline Details

1. Market Overview

2. Dashboard: Pipeline and Trial Analysis

3. CAR-T Clinical Development: Trial Details

4. TCR Clinical Development: Trial Details

5. TIL Clinical Development: Trial Details

6. Market Forecast: Assumptions

7. Market Forecast, 2015-2030

8. Preclinical Development

9. Inclusion / Exclusion Criteria

10. Abbreviations

List of Figures

Pipeline and Trial Details
Figure 1 T-cell Immunotherapy Products in Clinical Development: Distribution by Type of Therapy
Figure 2 T-cell Immunotherapy Trialsin Clinical Development: Distribution by Type of Therapy
Figure 3 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development
Figure 4 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development and Type of Therapy
Figure 5 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area
Figure 6 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
Figure 7 T-cell Immunotherapy Products in Clinical Development: Distribution by Target in the CAR-T Market
Figure 8 T-cell Immunotherapy Products in Clinical Development: Distribution by Targets in the TCR Market
Figure 9 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for CAR-T Therapy
Figure 10 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for TCR Therapy
Figure 11 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development
Figure 12 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development and Type of Therapy
Figure 13 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area
Figure 14 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
Figure 15 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status
Figure 16 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status and Type of Therapy 
Figure 17 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship
Figure 18 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship and Type of Therapy
Figure 19 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region
Figure 20 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region and Type of Therapy
Figure 21 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries
Figure 22 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries and Type of Therapy

Market Forecast Analysis
Figure A T-cell Immunotherapy Market Forecast, 2015-2030
Figure B T-cell Immunotherapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million

List of Tables

Pipeline Details
Table 1 CAR-T Clinical Development: Pipeline Details 
Table 2 TCR Clinical Development: Pipeline Details 
Table 3 TIL Clinical Development: Pipeline Details 
Table 4 Preclinical Development
Market Forecast Analysis
Table A Market Forecast: Assumptions 

Listed Companies

The following companies and organisations have been mentioned in the report:

  1. Abramson Cancer Center of the University of Pennsylvania
  2. Adaptimmune
  3. Affiliated Hospital to Academy of Military Medical Sciences
  4. Agency for Science, Technology and Research, China
  5. Albert Einstein College of Medicine, Yeshiva University
  6. Alex's Lemonade Stand Foundation
  7. Altor Biosciences 
  8. Amgen 
  9. Anhui General Hospital of Armed Police Forces
  10. Anhui Medical University & Hospital 
  11. AstraZeneca/MedImmune
  12. Atreca Therapeutics 
  13. Autolus
  14. Baxalta
  15. Beijing Doing Biomedical
  16. Bellicum Pharmaceuticals
  17. bluebird bio
  18. Bristol Myers Squibb
  19. California Institute of Technology 
  20. Cancer Prevention Research Institute of Texas
  21. Cancer Research UK
  22. CARsgen Therapeutics
  23. Celdara Medical
  24. Celgene
  25. Cell Therapy Catapult
  26. Cellectis
  27. Cellular Biomedicine Group
  28. Celyad
  29. Center for Cell and Gene Therapy, Baylor College of Medicine 
  30. Changzheng Hospital
  31. Children's Mercy Hospital, Kansas City
  32. Chinese PLA General Hospital
  33. Christie Hospital NHS Foundation Trust
  34. City of Hope Medical Center
  35. Clinica Universidad de Navarra
  36. CLL Global Research Foundation Alliance
  37. Conkwest
  38. Copenhagen University Hospital
  39. Cornell Weill Medicine, Cornell University
  40. Dana-Farber Cancer Institute
  41. Duke University Medical Center
  42. Erasmus Medical Center
  43. Fate Therapeutics 
  44. First Hospital of Jilin University
  45. Five Prime Therapeutics
  46. Formula Pharmaceuticals
  47. Fred Hutchinson Cancer Research Center
  48. Fuda Cancer Hospital
  49. Fudan University Shanghai Cancer Center 
  50. Glaxo Smith Kline
  51. H. Lee Moffitt Cancer Center and Research Institute
  52. Hadassah Medical Organization
  53. Harlev Hospital 
  54. Hefei Binhu Hospital
  55. Hoag Memorial Hospital Presbyterian
  56. Huazhong University of Science and Technology 
  57. iCarTAb BioMed
  58. iCell Therapeutics 
  59. Immatics
  60. Immunocore
  61. Intrexon Corporation
  62. James and Esther King Biomedical Research Program
  63. Janssen Pharmaceuticals 
  64. Jichi Medical University
  65. John Wayne Cancer Institute
  66. Jonsson Comprehensive Cancer Center
  67. Juno Therapeutics
  68. JW Biotechnology 
  69. Karolinska University Hospital
  70. Key Biologics
  71. King’s College London
  72. Kite Pharma
  73. Leiden University
  74. Leukaemia Lymphoma Research
  75. Lion Biotechnologies
  76. Lion TCR
  77. M.D. Anderson Cancer Center
  78. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  79. MaxCyte Therapeutics 
  80. MediGene
  81. Memorial Sloan Kettering Cancer Center
  82. Mie University
  83. Military Medical University
  84. Molmed S.p.A
  85. Mustang Bio
  86. Nantes University & Hospital
  87. Nantworks
  88. National Cancer Institute
  89. National Health and Medical Research Council
  90. National Heart, Lung, and Blood Institute
  91. National Institutes of Health
  92. Novartis
  93. Oxford BioMedica
  94. Peking University
  95. PersonGen Biomedicine
  96. Peter MacCallum Cancer Centre
  97. Pfizer
  98. Poseida Therapeutics
  99. Precision BioSciences
  100. Prometheus 
  101. RenJi Hospital
  102. Roger Williams Medical Center
  103. Roswell Park Cancer Institute
  104. Royal Adelaide Hospital Cancer Centre
  105. San Raffaele Hospital
  106. Seattle Children's Hospital
  107. Seattle Genetics
  108. Servier
  109. Shanghai GeneChem
  110. Shanghai Jiao Tong University
  111. Shanghai Tongji Hospital and University
  112. Sheba Medical Center
  113. Shenzhen Institute for Innovation and Translational Medicine
  114. Shenzhen Second People's Hospital
  115. Shionogi
  116. Sidney Kimmel Comprehensive Cancer Center
  117. Singapore General Hospital
  118. Sinobioway Cell Therapy
  119. Sirtex Medical
  120. Solving Kid’s Cancer
  121. Southwest Hospital
  122. St. Luke's Medical Center
  123. Sun Yat-Sen University
  124. Swedish Cancer Society
  125. Takara Bio
  126. Texas Children's Hospital
  127. The EVAN Foundation
  128. The First People's Hospital of Hefei
  129. The Methodist Hospital System
  130. The Netherlands Cancer Institute
  131. The Second Military Medical University
  132. The Third Military Medical University
  133. Theravectys
  134. Tianjin Medical University Cancer Institute and Hospital
  135. TILT Biotherapeutics 
  136. TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
  137. UNC Lineberger Comprehensive Cancer Center
  138. Universal Cells
  139. University College London
  140. University Health Network, Toronto
  141. University of Colorado
  142. University of Connecticut
  143. University of Florida
  144. University of Manchester
  145. University of Maryland Greenebaum Cancer Center
  146. University of Pennsylvania
  147. University of Southern California
  148. University of Zurich
  149. Unum Therapeutics
  150. Uppsala University
  151. ViroMed
  152. West China Hospital, Sichuan University 
  153. Wuhan General Hospital of Guangzhou Command 
  154. WuXi AppTec
  155. Xinqiao Hospital of Chongqing
  156. Xuzhou Medical College
  157. Zhejiang General Hospital of Armed Police
  158. Zhujiang Hospital
  159. Ziopharm Oncology

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 949

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com